Please assess the completion status of the following clinical trial:

Trial Title: METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic cardiac ischemic disease at least 4 months after one ore more myocardial infarctions in a stable phase of the disease without option for revascularization~* LVEF at echocardiography ≤ 40%~* Significant regional LV wall motion dysfunction in the infarct related territory~* Symptoms NYHA II-IV or CCS II-III (at least class III according to one of the two classifications)~* Patient agrees to comply with all follow-up evaluations~* Age \> 18 years old~* Patient has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent~Exclusion Criteria:~* Abnormal regional wall motion outside the infarct region~* Need for revascularization in a non infarct-related coronary within 6 months~* Patient has moderate to severe aortic valve disease, aortic or mitral prosthetic valve~* Patient has a significant mitral valve insufficiency (Effective Regurgitant office - ERO - \> 0.2 cm2 with possibility of mitral valve surgery~* Left ventricular thrombus at echocardiography~* LV-aneurysma planned surgical aneurysmectomy~* LV-wall thickness \< 5mm in the target territory~* Congenital heart disorder of hemodynamic relevance~* Known active infection or chronic infection with HIV, HBV or HCV~* Chronic inflammatory disease~* Serious concomitant disease with a life expectancy of less than one year~* Follow up impossible (no fixed abode, etc)~* Contraindication for cardiac MRI (i.e. pace maker, neurostimulator, claustrophobia)~* Severe renal failure (creatinine \> 250 mmol/l)~* Relevant liver disease (GOT \> 2x norm or spontaneous INR \> 1,5)~* Anemia (Hb \< 8.5 mg/dl), Thrombocytopenia (\< 100.000/µl)~* Women of child bearing potential or pregnancy~* Participation at a clinical trial in the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intramyocardial injection of BM cells (Type: EXPERIMENTAL): None
- Intramyocardial / intracoronary injection of BM cells (Type: EXPERIMENTAL): None
- control (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).